基本信息
views: 2
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Pedro Perdigão completed a BsC in Biochemistry in 2009 and a MsC in Molecular Biology and Genetics in 2011 at the University of Lisbon Faculty of Sciences, Portugal. During his MsC thesis, he expanded his interests to the virology and gene therapy fields to devise novel approaches to target and eliminate HIV reservoirs. In 2011, Pedro was awarded a PhD fellowship (SFRH/BD/81941/2011) from Fundação para a Ciência e Tecnologia to develop his PhD research at the University of Lisbon Faculty of Pharmacy under the supervision of Professor João Gonçalves and Dr Mariana Santa-Marta. His PhD work (published as first-author in Plos One and Molecular Therapy: Methods & Clinical Development) was focused on gene-targeted strategies to eliminate HIV latent cells through synthetic activators and suicide lentivectors. During this period, Pedro spent one year abroad working with the late Dr Carlos Barbas III, a leading researcher in genome engineering, at The Scripps Research Institute (San Diego, USA). Pedro also collaborated other research lines, from the evaluation of nosocomial infections ability to stimulate HIV reservoirs (co-first author manuscript in preparation) to the design of nanobody platforms for targeted delivery of anti-HIV siRNAs (co-authored in Cellular and Molecular Life Sciences).
From 2017 to 2019, Pedro took a Research Associate position at University College London Institute of Ophthalmology to integrate the group of Dr Jacqueline van der Spuy; his work was focused on CRISPR-based genome engineering of induced pluripotent stem cells to model AIPL1-related Leber congenital amaurosis (AIPL1-LCA), a severe inherited retinopathy causing blindness at an early stage. Pedro generated a human photoreceptor model based on AIPL1-knockout retinal organoids to monitor AIPL1-LCA progression and to optimize therapeutic interventions, which triggered a collaboration with a biotech company to test a gene therapy vector currently investigated for clinical application in AIPL1-LCA patients. Pedro also explored advances in CRISPR base editing to develop a novel approach for the precise in situ correction of mutations causing inherited retinopathies and made significant scientific contributions, including writing and integrating a Fight for Sight grant application that was ultimately funded. The ongoing work of Pedro’s postdoctoral research is expected to yield high-impact publications relevant to the treatment of inherited retinopathies.
In 2019, Pedro integrated the Molecular Therapies of Brain Disorders Group at the Center for Neuroscience and Cell Biology (CNC) as a Postdoctoral Researcher, supervised by Dr Luís Almeida. Here, he is building on his expertise on genome engineering platforms and gene therapy to design novel CRISPR-based strategies to model and rescue Machado Joseph-Disorder, an autosomal dominantly-inherited neurodegenerative subtype of ataxia.Pedro published 4 manuscripts (2 as first author and 2 as co-author) in peer-reviewed international journals and one book chapter as first author. He participated in 10 national and international research projects (one as Principal Investigator and one as Co-Investigator), including a FP7-funded European consortium dedicated to HIV research (HIVERA). Over his career, Pedro has engaged in mentoring undergraduate and predoctoral students (12), including the supervision of one MsC student and co-supervision of 2 PhD students, and has been an invited jury member to evaluate MSc candidates (2). Pedro has also presented his research in several national and international meeting, which awarded him four prizes (three best oral communications and one travel award).
Research Interests
Papers共 20 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Advanced drug delivery reviews (2024): 115346-115346
Mariana Martins, Ana RafaelaOliveira,Giuseppe Cammarata,Solange Martins,Pedro Perdigao,Ana Luisa Cardoso,Paulo Palma,Diana B. Sequeira,Joao Miguel Santos,Jose Pedro Vieira, Luis P. Almeida,Frederico Duque,
MEDICINEno. 13 (2023)
Cited0Views0Bibtex
0
0
Tess A V Afanasyeva,Dimitra Athanasiou,Pedro R L Perdigao, Kae R Whiting,Lonneke Duijkers,Galuh D N Astuti,Jean Bennett,Alejandro Garanto,Jacqueline van der Spuy,Ronald Roepman, Michael E Cheetham,Rob W J Collin
Molecular therapy. Methods & clinical development (2023): 522-531
MOLECULAR THERAPYno. 7 (2023): 2220-2239
International journal of molecular sciencesno. 6 (2023): 5912-5912
MOLECULAR THERAPYno. 7 (2023): 2220-2239
Pedro Perdigao, Miguel Dias,Sara Lopes,Rita Fernandes, Frederico Pena,Miguel Lopes,Rui Nobre,Thomas Gaj,Luis Pereira de Almeida
MOLECULAR THERAPYno. 4 (2023): 597-598
Cited0Views0Bibtex
0
0
Cited0Views0Bibtex
0
0
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn